Structural - APOLLO

TRANSCATHETER MITRAL VALVE REPLACEMENT WITH THE MEDTRONIC INTREPID (TMVR) SYSTEM IN PATIENTS WITH SEVERE SYMPTOMATIC MITRAL REGURGITATION

Dr. Talhat Azemi in conjunction with the Structural Heart Team are participating in this international trial evaluating the safety and efficacy of the Medtronic Intrepid TMVR system in patients with  moderate to severe or severe symptomatic mitral regurgitation who are unable to have standard transcatheter or surgical repair. 

Eligibility Criteria:

  • Patients with moderate‐to‐severe or severe symptomatic mitral regurgitation who are unable to have traditional transcatheter or surgical repair.

Please contact Jill Cloutier 860-972-2579 jill.cloutier@hhchealth.org or Maria Cardozo 860-972-5528 maria.cardozo@hhchealth.org for more information.